Individual-level precision diagnosis for coronavirus disease 2019 related severe outcome: an early study in New York
- PMID: 37443363
- PMCID: PMC10344938
- DOI: 10.1038/s41598-023-35966-z
Individual-level precision diagnosis for coronavirus disease 2019 related severe outcome: an early study in New York
Erratum in
-
Author Correction: Individual-level precision diagnosis for coronavirus disease 2019 related severe outcome: an early study in New York.Sci Rep. 2023 Sep 20;13(1):15621. doi: 10.1038/s41598-023-40792-4. Sci Rep. 2023. PMID: 37730883 Free PMC article. No abstract available.
Abstract
Because of inadequate information provided by the on-going population level risk analyses for Coronavirus disease 2019 (COVID-19), this study aimed to evaluate the risk factors and develop an individual-level precision diagnostic method for COVID-19 related severe outcome in New York State (NYS) to facilitate early intervention and predict resource needs for patients with COVID-19. We analyzed COVID-19 related hospital encounter and hospitalization in NYS using Statewide Planning and Research Cooperative System hospital discharge dataset. Logistic regression was performed to evaluate the risk factors for COVID-19 related mortality. We proposed an individual-level precision diagnostic method by taking into consideration of the different weights and interactions of multiple risk factors. Age was the greatest risk factor for COVID-19 related fatal outcome. By adding other demographic variables, dyspnea or hypoxemia and multiple chronic co-morbid conditions, the model predictive accuracy was improved to 0.85 (95% CI 0.84-0.85). We selected cut-off points for predictors and provided a general recommendation to categorize the levels of risk for COVID-19 related fatal outcome, which can facilitate the individual-level diagnosis and treatment, as well as medical resource prediction. We further provided a use case of our method to evaluate the feasibility of public health policy for monoclonal antibody therapy.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State.JAMA Netw Open. 2021 Feb 1;4(2):e2037069. doi: 10.1001/jamanetworkopen.2020.37069. JAMA Netw Open. 2021. PMID: 33533933 Free PMC article.
-
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085222 Free PMC article.
-
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5. Trials. 2021. PMID: 33430924 Free PMC article.
-
Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury.Am J Kidney Dis. 2021 Feb;77(2):204-215.e1. doi: 10.1053/j.ajkd.2020.09.002. Epub 2020 Sep 19. Am J Kidney Dis. 2021. PMID: 32961245 Free PMC article.
-
Early COVID-19 Hospitalizations Among New York State Residents with a History of Invasive Cancer.J Registry Manag. 2022 Winter;49(4):114-125. J Registry Manag. 2022. PMID: 37260811 Free PMC article.
Cited by
-
Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study.Ren Fail. 2024 Dec;46(2):2387933. doi: 10.1080/0886022X.2024.2387933. Epub 2024 Aug 23. Ren Fail. 2024. PMID: 39177234 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical